Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Twite, P. Stockton, S. Agarwal (Liverpool, United Kingdom). Azithromycin, a novel maintenance therapy in patients with chronic non-CF suppurative lung disease. Eur Respir J 2011; 38: Suppl. 55, 2544

Member's Comments

No comment yet.

Related content which might interest you: Azithromycin in the treatment of children with chronic inflammatory lung disease (CILD) Source: Eur Respir J 2004; 24: Suppl. 48, 391s Year: 2004 The association of bronchial colonization with the extent of lung lesions in children with non-CF chronic suppurative lung disease or recurrent pneumonia Source: Annual Congress 2009 - Fiberoptic bronchoscopy in the diagnosis of respiratory diseases in children Year: 2009 Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002 Immunomodulative therapy in young patients with non-CF bronchiectases exacerbations Source: Annual Congress 2009 - Bacterial infections of upper and lower respiratory tract in childhood Year: 2009 What is the role of prophylactic antibiotic therapy in chronic bronchitis or COPD? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 Compliance with nebulized therapy in patients with chronic lung disease Source: Eur Respir J 2001; 18: Suppl. 33, 59s Year: 2001 Antibiotic treatment and prophylaxis Source: Annual Congress 2006 - Infections and chronic obstructive lung diseases Year: 2006 Comparison of the efficacy of azythromycin and roxithromycin in the treatment of acute purulent exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 138s Year: 2001 Is infection screening in BAL fluid useful in children with chronic obstructive airway disease unresponsive to anti-asthmatic treatment? Source: Eur Respir J 2006; 28: Suppl. 50, 310s Year: 2006 A level of an alpha-1-proteinihibitor in patients with chronic bronchitis and lung tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 339s Year: 2003 The impact of COVID-19 on children with chronic suppurative lung disease Source: Virtual Congress 2021 – Respiratory function after COVID-19 and mechanical ventilation Year: 2021 Prevention and treatment of exacerbations of non-CF bronchiectasis Source: Eur Respir Monogr 2013; 60: 127-136 Year: 2013 Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007 Clinical features of chronic pulmonary aspergillosis treated with voriconazole in patients with chronic respiratory disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008 Azithromycin in the treatment of children with chronic airway disease (CAD) Source: Eur Respir J 2003; 22: Suppl. 45, 143s Year: 2003 Modulation of airway inflammation to prevent exacerbations of COPD Source: Eur Respir Rev 2005; 14: 78-82 Year: 2005 Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Azithromycin to prevent exacerbations of chronic obstructive pulmonary disease: a study in the real-world setting Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD Year: 2020 The role of pulmonary rehabilitation in the prevention of exacerbations of chronic lung diseases Source: Eur Respir Monogr 2017; 77: 224-246 Year: 2017